New Zealand - engelsk - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 0.6 mg/ml equivalent to 0.5 mg/ml salbutamol;   - solution for injection - 0.5 mg/ml - active: salbutamol sulfate 0.6 mg/ml equivalent to 0.5 mg/ml salbutamol   excipient: sodium chloride sodium hydroxide sulfuric acid water for injection - respiratory. salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. broncodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failing to respond to treatment with salbutamol may signal a need for urgent medical advice or treatment. relief of severe bronchospasm associated with asthma or bronchitis and for the treatment of status asthmaticus.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 1.2 mg/ml equivalent to 1 mg/ml salbutamol;   - solution for injection - 5mg/5ml - active: salbutamol sulfate 1.2 mg/ml equivalent to 1 mg/ml salbutamol   excipient: sodium chloride sodium hydroxide sulfuric acid water for injection - respiratory. salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. broncodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failing to respond to treatment with salbutamol may signal a need for urgent medical advice or treatment. relief of severe bronchospasm associated with asthma or bronchitis and for the treatment of status asthmaticus.

Israel - engelsk - Ministry of Health

glaxo smith kline (israel) ltd - salbutamol as sulfate - syrup - salbutamol as sulfate 2 mg / 5 ml - salbutamol - salbutamol - relief of bronchospasm in bronchial asthma of all types,chronic bronchitis,efmphysema.

Malta - engelsk - Medicines Authority

glaxo wellcome uk limited - salbutamol - nebuliser solution - salbutamol 5 mg/ml - drugs for obstructive airway diseases

Irland - engelsk - HPRA (Health Products Regulatory Authority)

pco manufacturing - salbutamol sulfate - nebuliser solution - 2.5 milligram

Irland - engelsk - HPRA (Health Products Regulatory Authority)

pco manufacturing - salbutamol sulfate - nebuliser solution - 2.5 milligram

Israel - engelsk - Ministry of Health

glaxo smith kline (israel) ltd - salbutamol as sulfate - powder for inhalation - salbutamol as sulfate 200 mcg/dose - salbutamol - salbutamol - relief of bronchospasm in broncial asthma of all types, chronic, bronchitis and emphysema.

Singapore - engelsk - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - salbutamol sulphate eqv salbutamol - tablet - salbutamol sulphate eqv salbutamol 2 mg

USA - engelsk - NLM (National Library of Medicine)

unit dose services - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - albuterol 90 ug - ventolin hfa is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ® ventolin hfa is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older. ventolin hfa is contraindicated in patients with a history of hypersensitivity to albuterol or any other components of ventolin hfa. rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate. pregnancy category c. teratogenic effects: there are no adequate and well-controlled studies of ventolin hfa or albuterol sulfate in pregnant women. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients being treated with albuterol. some of the mothers were taking multiple medications during their preg

USA - engelsk - NLM (National Library of Medicine)

unit dose services - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ventolin® hfa inhalation aerosol is indicated for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease. ventolin hfa is indicated for the prevention of exercise-induced bronchospasm in patients aged 4 years and older. ventolin hfa is contraindicated in patients with a history of hypersensitivity to any of the ingredients [see warnings and precautions (5.6), description (11)] . teratogenic effects: pregnancy category c. there are no adequate and well-controlled trials with ventolin hfa or albuterol sulfate in pregnant women. during worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been reported in the offspring of patients being treated with albuterol. some of the mothers were taking multiple medications during their pregnancies. no consistent pattern of defects can be discerned, and a relationship between albuterol use and congenital anomalies has not been established. animal reprod